[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334422-105":59,"doc-detail-334422-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-surveillance-strategy-for-intraductal-pancreatic-mucinous-neoplasms-criteria-for-discontinuation","The Surveillance Strategy for Intraductal Pancreatic Mucinous Neoplasms - Criteria for Discontinuation","","Reviewing intraductal papillary mucinous neoplasm (IPMN) surveillance, the study assesses pancreatic cancer risk and the cost-effectiveness of ongoing follow-up. It addresses concerns that increasing IPMN prevalence and low associated cancer incidence question the necessity of surveillance, while existing guidance lacks clear criteria to stop. Retrospective data from West of Scotland patients on surveillance were compared with age-matched controls. Results show most patients developed worrisome features or high-risk stigmata after median follow-up, and stable IPMNs had risk comparable to the general population. Surveillance discontinuation can be considered after 5 years in selected cohorts, reducing National Health Service costs.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-surveillance-strategy-for-intraductal-pancreatic-mucinous-neoplasms-criteria-for-discontinuation/334422/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-surveillance-strategy-for-intraductal-pancreatic-mucinous-neoplasms-criteria-for-discontinuation/334422.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the objective of this study on IPMN surveillance?","Question",{"text":112,"@type":113},"To review IPMN surveillance, evaluate pancreatic cancer risk, and assess the cost of surveillance, while identifying criteria for stopping surveillance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the study compare pancreatic cancer risk?",{"text":117,"@type":113},"It used retrospective surveillance data from patients in West of Scotland and compared outcomes with age-matched controls using standardized incidence ratios (SIRs).",{"name":119,"@type":110,"acceptedAnswer":120},"What conclusion did the study reach about discontinuing surveillance?",{"text":121,"@type":113},"Patients with stable IPMNs have a risk similar to the general population, and surveillance discontinuation may be considered after 5 years in selected patients, with potential cost savings.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334422,1790192641,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":4},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","ORIGINAL ARTICLE  \nThe Surveillance Strategy for Intraductal Pancreatic Mucinous Neoplasms  \nCriteria for Discontinuation  \nMari-Claire McGuigan, MRCS,*†✉ Rafaella Hadjicosti, BSc,‡ Andrew J. Cameron, MRCS,*† Maria Coats, PhD,* David Chang, PhD,*† Euan J. Dickson, MD,* David Holroyd, PhD,* Colin J. McKay, MD,* and Nigel B. Jamieson, PhD*†  \nObjective: To review the surveillance of intraductal papillary mucinous neoplasm (IPMN), the risk of pancreatic cancer, and the cost of surveillance.  \nBackground: The increasing IPMN prevalence and low pancreatic cancer associated with IPMN question the necessity and costeffectiveness of surveillance. Guidelines favor a “watch and wait”approach, lacking clarity on stopping surveillance. This study aims to identify patients with pancreatic cancer risk equivalent to their age group, create guidelines for stopping surveillance, and reduce National Health Service costs.  \nMethods: Retrospective analysis of patients with IPMN on surveillance in the West of Scotland. Clinicopathological data were collected. Endpoints included pancreatic cancer development and surveillance pathway cost estimation. Age-matched controls were used for comparison using standardized incidence ratios (SIRs) for pancreatic cancer.  \nResults: Of 746 patients, 27 (3 .62%) were resected. Three (0 .402%) developed pancreatic cancer and 44 (5.90%) developed worrisome features/high-risk stigmata after a median surveillance of 48 (interquartile range: 48) months. Two hundred twenty-one (29 .6%) had a stable cyst for at least 5 years and their SIR was 1.56 (95% CI: 0.04–8.71) . For patients ≥ 75 years with stable cysts for ≥ 5 years, SIR was 1 .71 (95% CI: 0 .03–3.42) . Patients ≥ 65 years with stable cysts of \u003C 15 mm for ≥ 5 years and patients with stable cysts of \u003C 10 mm for ≥ 5 years had SIRs of 0 . The cost of surveillance was £6,330.36 ($8,105.65) per resected patient and £2,032.78 ($2,602.85) per nonresected patient.  \nFrom the *Department of Surgery, Glasgow Royal Inﬁrmary; †School of Cancer Sciences, University of Glasgow; and ‡University of Glasgow Medical School, Wolfson Medical School Building,  \nUniversity Avenue, University of Glasgow, Glasgow, UK.✉ [mari-claire.mcguigan@glasgow.ac.uk](mari-claire.mcguigan@glasgow.ac.uk).  \nM.C.M. and R.H. are joint ﬁrst authors and contributed equally to this work.  \nAll relevant data are within this paper.  \nM.C.M., R.H., M.C., and N.B.J.:. conceptualization. M.C.M. and R.H.: data curation and analysis. M.C.M., R.H., A.J.C., M.C., D.C., E.J.D., D.H., C.J.M., and N.B.J.: data interpretation, writing–review and editing, and supervision. N.B.J.: ﬁnal approval.  \n[M.C.M. is](M.C.M. is) supported by the Chief Scientist Ofﬁce (Clinical Academic Fellowship) . [N.B.J. is](N.B.J. is) supported by Pancreatic Cancer UK (Early Detections Grant) . The remaining authors report no conﬂicts of interest.  \nCopyright © 2024 The Author(s) . Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.  \nDOI: 10.1097/SLA.0000000000006580  \nAnn Surg 􀀁 Volume 284, Number 1, July 2026  \nConclusions: Patients with stable IPMNs have similar pancreatic cancer risk as the general population. Surveillance discontinuation can be considered after 5 years in a cohort of patients, saving £106,211 . 19 ($136,020 .42) per year.  \nKey Words: economics, intraductal pancreatic mucinous neoplasms, IPMN, pancreatic cancer, pre-malignant, surveillance (Ann Surg 2026;284:119–126)  \nThe prevalence of intraductal papillary mucinous neo  \nplasms (IPMNs) has markedly increased in recent decades, primarily attributable to advancements in imaging technology leading to an increase in incidental diagnosis resulting in hei","cbCaieAnFj2fd1fZ","https://ap.wps.com/l/cbCaieAnFj2fd1fZ","pdf",288597,"English","# Objective\n# Background\n# Methods\n# Results\n# Conclusions\n# Key Words","[{\"question\":\"What was the objective of this study on IPMN surveillance?\",\"answer\":\"To review IPMN surveillance, evaluate pancreatic cancer risk, and assess the cost of surveillance, while identifying criteria for stopping surveillance.\"},{\"question\":\"How did the study compare pancreatic cancer risk?\",\"answer\":\"It used retrospective surveillance data from patients in West of Scotland and compared outcomes with age-matched controls using standardized incidence ratios (SIRs).\"},{\"question\":\"What conclusion did the study reach about discontinuing surveillance?\",\"answer\":\"Patients with stable IPMNs have a risk similar to the general population, and surveillance discontinuation may be considered after 5 years in selected patients, with potential cost savings.\"}]","The Surveillance Strategy for Intraductal Pancreatic Mucinous Neoplasms - Criteria for Discontinuation | PDF",1790006548]